Cita APA

Reck, M., Ciuleanu, T., Schenker, M., Zurawski, B., Menezes, J., Cobo, M., & Felip Font, E. (2021). First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

Citación estilo Chicago

Reck, M., Tudor Ciuleanu, M. Schenker, B. Zurawski, J. Menezes, Manuel Cobo, y Enriqueta Felip Font. First-line Nivolumab Plus Ipilimumab With Two Cycles of Chemotherapy Versus Chemotherapy Alone (four Cycles) in Advanced Non-small-cell Lung Cancer: CheckMate 9LA 2-year Update. 2021.

Cita MLA

Reck, M., et al. First-line Nivolumab Plus Ipilimumab With Two Cycles of Chemotherapy Versus Chemotherapy Alone (four Cycles) in Advanced Non-small-cell Lung Cancer: CheckMate 9LA 2-year Update. 2021.